SecBot SecBot
6-K ·Filed Sep 9, 2026

NVO

NOVO NORDISK A S
NEUTRAL
Impact 2/10
Horizondays Processed2mo ago SEC0001171843-26-005925
Notable filing: 6-K
Actionable Insight • Neutral

This filing is purely administrative, no change in buyback pace or strategy. Monitor future filings for any modification to the program or material corporate events. For a $200B market cap company, weekly buyback disclosures of this magnitude are not price-relevant.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$44.56
T+0 close · Sep 9, 2026 · via day close
Latest settled
−14.14%
T+20 · $38.26 · next T+60 in 16d
Vs SPY
−16.08%
α at T+20
Latest observation
−5.38%
T+46 · FF3 residual α
  1. T+0 · Sep 9 $44.56entry
  2. T+1 · 2mo ago −1.23%α −0.63% · $44.01
  3. T+5 · 2mo ago −6.40%α −5.74% · $41.71
  4. T+20 · 6w ago −14.14%α −16.08% · $38.26
  5. T+48 · todayOpen
  6. T+60 · in 16d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novo Nordisk filed a routine 6-K reporting weekly share repurchase activity under its existing DKK 15 billion buyback program. The company repurchased ~1.06M B shares for ~DKK 314.1M during the week of August 31–September 4, 2026, at an average price of ~DKK 297.5 per share. This is a standard periodic disclosure with no new material information, the buyback was announced months ago and is proceeding as planned.

Key Facts

  • Novo Nordisk repurchased 1,055,000 B shares during August 31–September 4, 2026, for a total transaction value of approximately DKK 314.1 million.
  • Accumulated repurchases under the program initiated May 6, 2026: 17,275,000 B shares for approximately DKK 5.22 billion.
  • Total repurchases since the broader 12-month program began February 4, 2026: 32,034,179 B shares for approximately DKK 9.02 billion, at an average price of DKK 281.63 per share.
  • Novo Nordisk now holds 46,074,876 B shares as treasury shares, representing 1.0% of total share capital of 4,465,000,000 A and B shares.
  • The overall program authorizes up to DKK 15 billion in repurchases over 12 months from February 4, 2026.

Financial Impact

Routine buyback execution, approximately DKK 314.1M in repurchases for the week. No new authorization or change in program size.

share counttreasury shares

Risk Factors

  • None, this is a routine disclosure of ongoing share repurchases with no new authorization or change in terms.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
31% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-005925
Document: 0001171843-26-005925-index-headers.html0001171843-26-005925
Document: 0001171843-26-005925-index.html0001171843-26-005925
Document: 0001171843-26-005925.txt0001171843-26-005925

US Market Status

Market Closed · Opens in 7h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026